Get the content you want anytime you want.

Healthcare professionals and thought leaders share their knowledge and insights on an array of infectious disease topics

Latest Videos

Implications of Plazomicin Approval for Patients with cUTI
Jason Gallagher, PharmD, discusses the clinical implications of the approval of plazomicin for health care providers and patients.
Resistance Issues and Resistance Factors With MDR Bacteria
Jason Gallagher, PharmD, provides an overview of the resistance issues and resistance factors of specific pathogens that develop multidrug resistance.
Treating <i>Pseudomonas</i> Infections With Zerbaxa or Avycaz
Panelists provide their perspective on the appropriate settings in which to use Zerbaxa (ceftolozane) or Avycaz (ceftazidime/avibactam) for Pseudomonas infections and reflect on which dosing methods are the safest.
<i>Pseudomonas</i> Infections: Secondary Approach to Treatment
Panelists discuss their personal approaches to treating Pseudomonas infections when an earlier strategy has failed, taking into consideration past treatments, a patient’s sepsis status, and timely decision making.
Understanding the Prevalence of ABSSSI in the Community
Panelists discuss the prevalence of acute bacterial skin and skin structure infections, including MRSA, in the community, as well as risk factors, susceptibility, and increased resistance to oral antibiotics such as Keflex.
An Overview of ABSSSI
Peter L. Salgo, MD; Yoav Golan, MD; and Bruce M. Jones, PharmD, BCPS, identify the commonalities of ABSSSI, including the predominant pathogens, such as Staphylococcus aureus and Streptococcus, and gram-positive infections.
Pseudomonas Infections: Selecting Upfront Antibiotics
Panelists reflect on their personal upfront approaches to treating Pseudomonas infections before lab results return, considering monotherapy versus treatment cocktails and the inherent risks that need to be accounted for.  
Initial Therapy for MDR Bacteria and Antibiotic Resistance
Jason Gallagher, PharmD, discusses the importance of appropriate initial therapy and the mechanism of resistance of multidrug-resistant bacteria.
Big advances in treatment can